Login / Signup

Multivalent viral particles elicit safe and efficient immunoprotection against Nipah Hendra and Ebola viruses.

Duncan G IthinjiDavid W BuchholzShahrzad EzzatpourI Abrrey MonrealYu CongJulie SahlerAmandip Singh BangarBrian ImbiakhaViraj UpadhyeJanie LiangAndrew MaBirgit Bradel-TrethewayBenjamin KazaYao-Yu YeoEun Jin ChoiGunner P JohnstonLouis HuzellaErin KollinsSaurabh DixitShuiqing YuElena PostnikovaVictoria OrtegaAvery AugustMichael R HolbrookHector C Aguilar
Published in: NPJ vaccines (2022)
Experimental vaccines for the deadly zoonotic Nipah (NiV), Hendra (HeV), and Ebola (EBOV) viruses have focused on targeting individual viruses, although their geographical and bat reservoir host overlaps warrant creation of multivalent vaccines. Here we explored whether replication-incompetent pseudotyped vesicular stomatitis virus (VSV) virions or NiV-based virus-like particles (VLPs) were suitable multivalent vaccine platforms by co-incorporating multiple surface glycoproteins from NiV, HeV, and EBOV onto these virions. We then enhanced the vaccines' thermotolerance using carbohydrates to enhance applicability in global regions that lack cold-chain infrastructure. Excitingly, in a Syrian hamster model of disease, the VSV multivalent vaccine elicited safe, strong, and protective neutralizing antibody responses against challenge with NiV, HeV, or EBOV. Our study provides proof-of-principle evidence that replication-incompetent multivalent viral particle vaccines are sufficient to provide protection against multiple zoonotic deadly viruses with high pandemic potential.
Keyphrases
  • sars cov
  • coronavirus disease
  • genetic diversity
  • cancer therapy
  • drug delivery
  • zika virus
  • climate change
  • dengue virus
  • heat shock protein